Quotables
"Radio has no future."
Lord Kelvin, British mathematician and physicist ; 1897
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7678767 | Glue compositions for lung volume reduction The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for examp... | 03/16/2010 |
| 7678768 | Physiologically-active composition based on collagen The present invention concerns a physiologically active composition which contains an enzymatically hydrolysed collagen as the active component I and at least one component of the non-vitamin type having anti-oxidative and/or anti-inflammatory properties as the acti... | 03/16/2010 |
| 7678769 | Hepatocyte growth factor receptor splice variants and methods of using same Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related... | 03/16/2010 |
| 7674770 | Anti-tumor drug, medicament, composition, and use thereof An active polypeptide comprising the amino acid sequence of SEQ ID NO: 3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO: 3, or fragments thereof having at least 21 contiguous amino acids, or peptides h... | 03/09/2010 |
| 7674769 | Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI) Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous ... | 03/09/2010 |
| 7671021 | Peptides that home to tumor lymphatic vasculature and methods of using same The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering ... | 03/02/2010 |
| 7671023 | Amylin agonist for treating depression, anxiety disorder and schizophrenia Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions asso... | 03/02/2010 |
| 7671019 | 3-deoxyglucosone and skin The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG s... | 03/02/2010 |
| 7671018 | Delivery system for heparin-binding growth factors New uses of proteoglycans to bind and present growth factors, methods of accelerating wound, tissue or bone repair using such proteoglycans, pharmaceutical compositions of such proteoglycans, and scaffolds coated with such proteoglycans are disclosed. The proteoglyc... | 03/02/2010 |
| 7671022 | Methods for treating cardiovascular disease using a soluble CTLA4 molecule The present invention relates to compositions and methods for treating cardiovascular system diseases by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands. ... | 03/02/2010 |
| 7671024 | OBG3 globular head and uses thereof The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reduc... | 03/02/2010 |
| 7671020 | Methods of increasing cartilage deposition using FGF homologs The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage inj... | 03/02/2010 |
| 7666837 | Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins Methods and compositions for producing secreted soluble receptors and biologically active polypeptides in trimeric forms are disclosed. The process involves fusing the DNA template encoding a soluble receptor with a ligand binding domain or biologically active polyp... | 02/23/2010 |
| 7666838 | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provid... | 02/23/2010 |
| 7666835 | Oxyntomodulin for preventing or treating excess weight Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake. ... | 02/23/2010 |
| 7666836 | Method for the therapeutic management of endometriosis The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to ano... | 02/23/2010 |
| RE41133 | Glucagon-like peptide-1 crystals The invention provides individual tetragonal flat rod shaped or plate-like crystals of glucagon-like peptide-1 related molecules, processes for their preparation, compositions and methods of use. The crystal preparations exhibit extended time action in vivo and are ... | 02/16/2010 |
| 7662781 | Immunopotentiating agent Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc has been inevitable. The present invention intends to provide a therapeutic method that ensures less ... | 02/16/2010 |
| 7662780 | Administering hypocretin to obese individuals The invention provides compositions and methods for treatment and prophylaxis of weight disorders. Such methods entail administering to an individual a therapeutically or prophylactically effective dosage regime of a hypocretin or an agonist thereof, and monitoring ... | 02/16/2010 |
| 7659248 | Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins Stabilized aqueous compositions of tissue factor pathway inhibitor (TFPI) or TFPI variants comprise a solubilizing agent, an antioxidant, and a buffer. The combination of a solubilizing agent and an antioxidant can lead to a significant improvement in the storage li... | 02/09/2010 |
| 7659249 | Membrane-permeable NFAT inhibitory peptide The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibi... | 02/09/2010 |
| 7659250 | BMP-7 variant compositions, methods and uses Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed. ... | 02/09/2010 |
| 7659247 | Production of a von Willebrand factor preparation having a high specific activity This invention relates to a process for the production of a von Willebrand factor preparation having a high specific activity, hydroxylapatite being used as a chromatography medium. ... | 02/09/2010 |
| 7655628 | Method for treating liver cirrhosis or interstitial pulmonary fibrosis The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis. ... | 02/02/2010 |
| 7655626 | Antiangiogenic peptides The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activi... | 02/02/2010 |
| 7655627 | Muteins of fibroblast growth factor 21 The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host... | 02/02/2010 |
| 7648962 | Natriuretic compounds, conjugates, and uses thereof Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activi... | 01/19/2010 |
| 7648964 | Use of lacritin in promoting ocular cell survival The present invention relates to the use of lacritin, and fragments, derivatives, and homologs thereof, and nucleic acid sequences encoding that protein. The invention relates to the use of lacritin as a growth factor human corneal epithelial cells and other select ... | 01/19/2010 |
| 7648963 | Molecules of the PYRIN/NBS/LRR protein family and uses thereof Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 proteins, the in... | 01/19/2010 |
| 7645739 | Modified annexin compositions and methods of using same Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-re... | 01/12/2010 |
| 7642241 | Methods of enhancing functioning of the large intestine The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue o... | 01/05/2010 |
| 7642240 | Bioconjugates comprising sulfated polysaccharides and their uses The present invention provides bioconjugates comprising a sulfated polysaccharide such as alginate sulfate and hyaluronan sulfate and at least one bioactive polypeptide capable of binding a sulfate group of said sulfated polysaccharide. The bioactive polypeptide can... | 01/05/2010 |
| 7642242 | PRO34128 polypeptides The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molec... | 01/05/2010 |
| 7642236 | Recombinant lubricin molecules and uses thereof Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided. | 01/05/2010 |
| 7642237 | Growth/differentiation factor of the TGF-β family The invention concerns a protein of the TGF-β family, the DNA coding therefor and a pharmaceutical composition containing the protein. ... | 01/05/2010 |
| 7642238 | Molecular determinants of myeloma bone disease and uses thereof To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were com... | 01/05/2010 |
| 7642239 | Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2... | 01/05/2010 |
| 7638493 | Artificial pulmonary surfactant compositions and use of the same The artificial pulmonary surfactant composition according to the present invention comprises a lipid mixture system containing no protein or peptide or a protein/peptide-lipid mixture prepared by adding a protein or a peptide to the above lipid mixture system. The a... | 12/29/2009 |
| 7638492 | Methods of upmodulating an immune response with non-activating forms of B7-4 The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in... | 12/29/2009 |
| 7638490 | Methods of affecting feeding and weight in mammals by administration of relaxin-3 Relaxin-3 is found to have feeding-stimulating activity, body weight increasing activity, and fat weight increasing activity when intracerebroventricularly administered to rats through observation of amount of feeding, body weight and fat weight after administration... | 12/29/2009 |